Background: Previous epidemiological studies have focused on the prevalence of primary glomerulonephritis (GN), but few have explored long-term patient outcomes. This study was conducted to investigate the long-term patient and renal outcomes of primary GN. Methods: A total of 1,943 biopsy-proven primary GN patients were included. The outcomes were mortality and end-stage renal disease (ESRD) progression. The relative mortality rate was expressed by the standardized mortality ratio (SMR) and the 95% confidence interval (CI). Results: During the median follow-up of 90 months, 325 (16.7%) patients progressed to ESRD and 164 (8.4%) patients died. Patients with minimal change disease exhibited the best renal and patient outcomes, whereas those with membranoproliferative GN had the worst. IgA nephropathy patients appeared to have a good survival rate in spite of their considerable progression to ESRD, and focal segmental glomerulosclerosis patients showed poor renal and patient outcomes. Mortality was 67% higher in primary GN patients than in the age- and sex-matched general population (SMR, 1.67; 95% CI, 1.42–1.95). The difference was more prominent in women (SMR, 2.95; 95% CI, 2.27–3.77) than in men (SMR, 1.31; 95% CI, 1.07–1.60). Renal risk factors, e.g. hypertension, proteinuria and initial renal dysfunction, were all associated with higher mortality, and the relative mortality rate increased with the number of risk factors. Conclusions: In patients with primary GN, mortality is significantly higher than in the age-/sex-matched general population, especially in women. Moreover, the presence of renal risk factors is positively associated with both relative mortality and progression to ESRD.

Keywords:
End-stage renal disease, Glomerulonephritis, Mortality, Renal risk factors
1.
McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011;26:414–430.
2.
Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H: The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 2009;24:870–876.
3.
Naumovic R, Pavlovic S, Stojkovic D, Basta-Jovanovic G, Nesic V: Renal biopsy registry from a single centre in Serbia: 20 years of experience. Nephrol Dial Transplant 2009;24:877–885.
4.
Hanko JB, Mullan RN, O’Rourke DM, McNamee PT, Maxwell AP, Courtney AE: The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009;24:3050–3054.
5.
Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, Kim BS, Kang SW, Choi KH, Han DS, Jeong HJ, Lee HY: Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant 2009;24:2406–2410.
6.
Panichi V, Pasquariello A, Innocenti M, Meola M, Mantuano E, Beati S, Paoletti S, Consani C, Puccini R, Casarosa L, Gattai V, Filippi C, Moriconi L, Barsotti G, Rindi P, Palla R: The Pisa experience of renal biopsies, 1977–2005. J Nephrol 2007;20:329–335.
7.
Swaminathan S, Leung N, Lager DJ, Melton LJ 3rd, Bergstralh EJ, Rohlinger A, Fervenza FC: Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006;1:483–487.
8.
Covic A, Schiller A, Volovat C, Gluhovschi G, Gusbeth-Tatomir P, Petrica L, Caruntu ID, Bozdog G, Velciov S, Trandafirescu V, Bob F, Gluhovschi C: Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. Nephrol Dial Transplant 2006;21:419–424.
9.
Nair R, Walker PD: Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455–1458.
10.
Braden GL, Mulhern JG, O’Shea MH, Nash SV, Ucci AA Jr, Germain MJ: Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35:878–883.
11.
van de Luijtgaarden MWM, Noordzij M, Wanner C, Jager KJ: Renal replacement therapy in Europe – a summary of the 2009 ERA–EDTA Registry Annual Report. Clin Kidney J 2012;5:109–119.
12.
Jin DC: Current status of dialysis therapy in Korea. Korean J Intern Med 2011;26:123–131.
13.
Bohle A, Wehrmann M, Bogenschutz O, Batz C, Vogl W, Schmitt H, Muller CA, Muller GA: The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 1992;188:908–924.
14.
Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Research Group on Progressive Chronic Renal Disease. Nephron 1999;82:205–213.
15.
Moranne O, Watier L, Rossert J, Stengel B: Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM 2008;101:215–224.
16.
Iseki K, Miyasato F, Uehara H, Tokuyama K, Toma S, Nishime K, Yoshi S, Shiohira Y, Oura T, Tozawa M, Fukiyama K: Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004;66:914–919.
17.
Heaf J, Lokkegaard H, Larsen S: The epidemiology and prognosis of glomerulonephritis in Denmark 1985–1997. Nephrol Dial Transplant 1999;14:1889–1897.
18.
Chou YH, Lien YC, Hu FC, Lin WC, Kao CC, Lai CF, Chiang WC, Lin SL, Tsai TJ, Wu KD, Chen YM: Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 2012;7:1407–1408.
19.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
20.
Zucchelli P, Ponticelli C, Cagnoli L, Passerini P: Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 1987;2:73–78.
21.
Sprangers B, Bomback AS, Cohen SD, Radhakrishnan J, Valeri A, Markowitz GS, D’Agati V, Appel GB: Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center. Am J Nephrol 2012;36:78–89.
22.
Cattran DC, Kim J: Is long-term prediction in membranous nephropathy (MGN) better than the weatherman’s forecast capacity? Clin J Am Soc Nephrol 2012;7:1203–1205.
23.
McQuarrie EP, Stirling CM, Geddes CC: Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol Dial Transplant 2012;27:235–242.
24.
Cattran DC, Reich HN, Kim SJ, Troyanov S: Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin J Am Soc Nephrol 2011;6:1591–1598.
25.
Waldman M, Austin HA 3rd: Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1617–1630.
26.
Floege J, Eitner F: Current therapy for IgA nephropathy. J Am Soc Nephrol 2011;22:1785–1794.
27.
Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernandez-Juarez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga M: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697–704.
28.
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005;16:1061–1068.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.